米ダウ 日本で医薬製造受託 CBCと契約
March 14, 2003 Dowpharma
Dowpharma Signs Agreement with Japanese Distributor to Market Pharmaceutical Services in Japan
Dowpharma, a business unit of The Dow Chemical Company signed an agreement with CBC Co. Ltd (Tokyo, Japan) to be its representative in marketing its pharmaceutical services to Japanese drug makers. The agreement was developed out of an existing relationship that CBC had with Chirotech, which was part of the Ascot acquisition that Dow made in 2001. Chirotech, a global leader in chiral technology, is part of the Dowpharma business.
"CBC Co. Ltd. has considerable expertise in pharmaceutical products and services while understanding our offering, so they will be able to communicate our capabilities to perspective customers", states Gwin Bompas, Dowpharma commercial director for Europe and Asia/Japan. CBC will also assist Dowpharma in obtaining technology licenses from identified Japanese authorities and companies. Due to the language, cultural and time zone differences, CBC will interface as Dowpharma's local agent to help Dowpharma grow its business in the Japanese pharmaceutical market.
As the Japanese government recently made it legal for pharmaceutical companies to outsource the manufacture of active pharmaceutical ingredients Dowpharma believes it's positioned very favorably with its extensive offering. Dowpharma has a large toolbox of enabling technologies, including a wide selection of industrially ready chiral technologies, along with a stellar regulatory record that will benefit pharmaceutical companies to bring their drugs to market quicker and more efficiently. "We see growth opportunities, as Japan is one of the largest pharmaceutical markets and will need contract manufacturing organizations that can support a wide range of offerings/services along with customized solutions, and Dowpharma has the breadth and depth to meet a variety of needs," states Bompas.
CBC and Dowpharma will be exhibiting at the upcoming event, CPhI Japan which will be held April 15-17 in Tokyo.
As part of Dow’s Custom & Fine Chemicals global business unit, Dowpharma serves the pharmaceutical and biopharmaceutical industries with innovative technology, products and services for clients in drug discovery, development, manufacturing and delivery. Dowpharma combines the resources and capabilities of several entities to create a single, market focused organization with broad service and support capabilities for large and emerging pharmaceutical companies.
Dowpharma services include process development, route selection, methods development and associated analytical services and manufacturing and scale-up from the bench through clinical trials and to commercial launch. Dowpharma currently manufactures small molecule Active Pharmaceutical Ingredients (APIs) and intermediates, oligonucleotides, peptides, cGMP polymers and proteins from microbial fermentation.
Dowpharma has a 20-plus year history of pristine cGMP regulatory compliance in the organic synthesis of APIs and pharmaceutical intermediates with the ability to provide client support in filing and validation strategies. The business also manufactures a long list of scaffolds and fine chemicals of interest to the drug development community. This business combines personnel and assets from Dow’s Contract Manufacturing Services business with those from Chirotech Technology Limited, Mitchell Cotts Chemicals, Hampshire Chemical Corp., and Dow Biopharmaceutical Contract Manufacturing Services. Dowpharma operates research, process development and manufacturing facilities in North America and Europe.
Dow is a leading science and technology company that provides innovative chemical, plastic and agricultural products and services to many essential consumer markets. With annual sales of $27 billion, Dow serves customers in more than 170 countries and a wide range of markets that are vital to human progress, including food, transportation, health and medicine, personal and home care, and building and construction, among others. Committed to the principles of Sustainable Development, Dow and its approximately 50,000 employees seek to balance economic, environmental and social responsibilities.
April 15, 2003 Financial Times
Dow Pharma to start contract manufacturing in Japan.
Dow Pharma is to start contract drug manufacturing in Japan using facilities for specialty fine chemicals production acquired from Ascot of the UK in 2001. Dow Pharma has acquired the licence to the catalytic asymmetric synthesis technology of a Nobel Prize winning Japanese scientist and is expected to use the technology in the development of chiral selective high yield catalysts. Dow Pharma estimates the domestic market for pharmaceutical intermediates to be Yen 100-150 bn.
Pharmaceutical Services from Dow
Secures Exclusive Rights to DuPHOSTM Asymmetric（不斉）Hydrogenation Technology for
The Pharmaceutical Services business unit of The Dow Chemical Company has secured exclusive rights to DuPontTM DuPHOSTM asymmetric hydrogenation technology, licensed from DuPont for pharmaceutical applications.
Chemocatalysis provides access to a wide range of enantiomerically pure compounds, and asymmetric hydrogenation processes are an especially useful method of chemocatalysis for large-scale commercial production using simple reaction conditions. Transition metal complexes derived from the DuPHOSTM family of ligands are amongst the best understood and most broadly applicable catalysts used in asymmetric hydrogenation.
“Asymmetric chemocatalysis is a rapidly developing area of innovation, as researchers look for new ligands and catalysts that are more active, more selective, and more broadly applicable in the commercial arena," explained Nick Hyde, Business Director for Pharmaceutical Services. "We use asymmetric chemocatalysis extensively, in applications ranging from the manufacture of single-enantiomer chiral intermediates from prochiral precursors, to the building of more complex structures such as chiral scaffolds for pharmaceutical discovery.”
“This agreement signifies Dow’s recognition of the importance of the DuPHOSTM technology to our customers and our commitment to build on previous development efforts and improvements from Chirotech,” Hyde continued. Chirotech Technology Limited originally licensed from DuPont in 1995 the exclusive rights for the commercial use of DuPHOSTM technology, and of related BPE and ferrocene-based ligands, for the pharmaceutical industry. Acquired by Dow in 2001 as part of the Ascot acquisition, Chirotech has been integrated into Dow's Pharmaceutical Services business.
“When the original Chirotech licensing agreement was signed, only research quantities of DuPHOSTM products had been made,” Hyde added. “Today, DuPHOSTM is a fully developed manufacturing technology for industrial use backed by a robust supply chain. We routinely manufacture these products in quantities sufficient for multi-ton production of value-added chiral building blocks and advanced pharmaceutical intermediates.”
“This agreement is another reason why Chirotech was such good strategic fit for our Pharmaceutical Services business unit,” Hyde added. “We now have an enviable number of choices available in our catalyst toolbox. In addition to well-established DuPHOSTM technology, we offer a broad range of complementary catalyst systems for asymmetric hydrogenation processes. In particular, under Chirotech's license from the Japan Science and Technology Corporation（科学技術振興事業団）, we have access to the powerful and versatile Noyori technology for ketone hydrogenation.”
Pharmaceutical Services follows a flexible approach to satisfying customer needs for catalyst technology. Pharmaceutical Services will manufacture products (building blocks, advanced intermediates, and APIs) for customers where chemocatalysis is used as a key step. Customers can also license catalysts from Pharmaceutical Services for use in their own manufacturing facilities, and they can utilize Dow's screening and development service to identify the best choice of catalyst for their individual situation.
About Pharmaceutical Services from Dow
The Pharmaceutical Services business is part of Dow’s Custom & Fine Chemicals global business unit. This business is exclusively dedicated to serving the pharmaceutical and biopharmaceutical industries with innovative technology, products and services to clients in drug discovery, development, manufacturing and delivery. Manufacturing services include process development, route selection, methods development and associated analytical services and manufacturing and scale up from the bench through commercial launch. Pharmaceutical Services currently manufactures small molecule APIs, oligonucleotides, peptides, cGMP polymers and proteins from microbial fermentation.
Pharmaceutical Services has a 20-plus year history of pristine cGMP regulatory compliance in the organic synthesis of Active Pharmaceutical Ingredients (APIs) and pharmaceutical intermediates with the ability to provide client support in filing and validation strategies. Pharmaceutical Services also manufactures a long list of scaffolds and fine chemicals of interest to the drug development community. This business combines personnel and assets from Dow’s original Contract Manufacturing Services business with those from Chirotech Technology Limited, Mitchell Cotts Chemicals, Hampshire Chemical Corp., and Dow Biopharmaceutical Contract Manufacturing Services. Pharmaceutical Services operates research, process development and manufacturing facilities in North America and Europe.
For more information on Pharmaceutical Services, visit www.dowpharma.com.
Dow is a leading science and technology company that provides innovative chemical, plastic and agricultural products and services to many essential consumer markets. With annual sales of $28 billion, Dow serves customers in more than 170 countries and a wide range of markets that are vital to human progress, including food, transportation, health and medicine, personal and home care, and building and construction, among others. Committed to the principles of Sustainable Development, Dow and its approximately 50,000 employees seek to balance economic, environmental and social responsibilities.
DuPontTM and DuPHOSTM are trademarks of E.I. du Pont de Nemours and Company.
Dowpharma is exclusively
dedicated to serving the pharmaceutical and biopharmaceutical
industries, providing product development, process development,
and manufacturing of intermediates and active pharmaceutical
ingredients. We also offer proprietary advanced chiral
intermediates and fine chemicals of interest to the
pharmaceutical and biopharmaceutical industries.
Our business combines selected personnel and assets from Dow's original Contract Manufacturing Services business with those from acquired companies, including Chirotech Technology Limited (chiral chemo-catalysis and biocatalysis), Mitchell Cotts, Hampshire Chemical Corp. (hydrogen cyanide derivatives) and Dow Biopharmaceutical Contract Manufacturing Services, as well as other pharmaceutical services （such as ANGUS Chemical）within Dow.
We have also formed a number of strategic alliances with leaders in carbohydrate-based pharmaceuticals and nutraceuticals, chiral compounds, and unique separation processes.
The result is one of the broadest and deepest global outsourcing capabilities in the industry with more than 20 years experience in manufacturing and scale up services from the bench through commercial launch and other innovative technologies, products, and services for drug development and delivery.
Dow Declares Offer to Acquire
Ascot Wholly Unconditional
The Dow Chemical Company (NYSE: Dow) announced today that its wholly owned subsidiary, Dow UK plc, has declared its offer to acquire Ascot Plc (LSE: AST) wholly unconditional. Dow UK plc will proceed to acquire the remaining outstanding shares and options to complete this transaction and apply to the London Stock Exchange for the cancellation of the listing of Ascot shares.
Dow announced the tender offer to acquire Ascot Plc on March 29, 2001. Ascot is involved in contract manufacturing and the production of specialty and fine chemicals, and has annual chemical sales of approximately $335 million (£221 million).
"We are very pleased that this transaction has been successfully completed," stated Andrew Liveris, business group president of Dow's Performance Chemicals' business group. "Ascot's fine and specialty chemical products are complementary to our existing performance chemicals portfolio and extend our ability to provide broader solutions to our customers' key markets. Performance Chemicals has been rapidly growing for the past several years, with our acquisitions of Hampshire Chemical, ANGUS Chemical and a major part of Union Carbide. We've created a true specialty chemicals powerhouse that has an unmatched product offering for our customers."
Dow plans to integrate Ascot's four businesses - Haltermann Custom Processing, Haltermann Products, Chirotech, and Mitchell Cotts - into its Custom & Fine Chemicals global business unit that also includes Dow Contract Manufacturing Services and ANGUS Chemical.
George Biltz, business vice president of Dow's Custom & Fine Chemicals global business unit, added, "As a world leader in chiral and distillation technologies, Ascot expands Dow's already strong portfolio of development and contract manufacturing capabilities for the chemical, pharmaceutical, and agricultural chemical industries. It builds upon the successful foundation of our Contract Manufacturing Services business and expands our asset base in Europe and the United States. Ascot's European cGMP (current Good Manufacturing Practices) facilities are especially attractive. We are very excited about the opportunity to leverage Ascot's valuable capabilities with Dow's global integrated manufacturing asset position."
Biltz also noted that Ascot's niche products complement Dow's offerings to customers in coatings, inks, and household and personal care products industries. The Haltermann and Chirotech names are very well known within the industry and will continue to add value within Dow's broad product and services portfolio.
"Chirotech expertise in chiral chemo-catalysis and biocatalysis is highly complementary to Dow's emerging strength in biotechnology and biomanufacturing," stated Biltz. "This acquisition is a continuation of Dow's investment in biotechnology and asymmetric synthesis capabilities, which began with the acquisition of Mycogen, investments in our biotechnology capability in San Diego and most recently with the acquisition of all of the assets of Collaborative BioAlliance, Inc. (now Dow Biopharmaceutical Contract Manufacturing Services). Dow has further supplemented these capabilities through agreements with Diversa Corporation for the joint development of chiral compounds."
Prior to the announcement of Dow's offer, Ascot disposed of Nationwide Refrigeration Supplies (NRS), its refrigeration distribution business. In addition, to fulfill a condition to close the Ascot acquisition, Dow required Ascot to dispose of its non-core property portfolio. Ascot sold its Property Subsidiaries to Ashtenne Holdings, Plc ("Ashtenne"), a UK publicly quoted property company for £44.11 million.
Ascot's Specialty Chemicals and Fine Chemicals businesses include:
|：||・||Haltermann Custom Processing:|
|Haltermann is a world leader in custom chemical processing, operating plants in Belgium, Germany, the United States and the United Kingdom. Haltermann works with many of the world's leading petrochemical and specialty chemical companies using continuous and batch distillation and reaction technology to provide its custom processing services.|
Located in Germany with sales offices in Belgium, Romania, Sweden, France and the United Kingdom (as well as more than 40 agents and distributors), Haltermann's major customers are in the automotive, graphic arts, chemical and pharmaceutical industries. Its main products are printing ink distillates, ultra pure solvents, performance esters, reference fuels, low-boiling hydrocarbons and surfactants.
Chirotech is a leader in chiral technology, which enables the manufacture of drugs with higher efficacy and lower side effects. Its main products, which consist of single enantiomer scaffolds and building blocks for drug discovery, advanced intermediates and active pharmaceutical ingredients, are primarily sold to some of the world's major pharmaceutical companies.
Mitchell Cotts' customers are major companies in the pharmaceutical and agricultural chemical industries for whom it manufactures higher value chemical materials under contract and also undertakes process development work.
Hampshire Chemical Corp. http://www.dow.com/hampshire/
Hampshire Chemical Corp. is a global leader in hydrogen cyanide chemistry as well as other chemistries and technologies. A wholly owned subsidiary of The Dow Chemical Company, Hampshire supplies specialty anionic surfactants based on Schotten-Baumann technology for personal care products and other applications, industrial dispersants, glycine, iminodiacetic acid, as well as hydrogen cyanide intermediates and derivatives, and custom synthesis. The Evans Chemetics unit specializes in the development of organic divalent sulfur compounds and other chemical specialties.
Hampshire Chemical Corporation has dedicated plant sites in Nashua, New Hampshire; Deer Park, Texas; Waterloo, New York; Owensboro, Kentucky; and Seal Sands, England. In 1998 Hampshire, formerly a member of the Sentrachem Group, became a wholly owned subsidiary of The Dow Chemical Company. Operating as part of Dow's diverse portfolio of Specialty Chemicals businesses, Hampshire remains headquartered in Lexington, Massachusetts.
(In 1997 Sentrachem was purchased by Dow Corporation)
Biopharmaceutical Contract Manufacturing Services
Dowpharma offers a broad spectrum of technology capabilities, as well as development and manufacturing services for the production of recombinant proteins from microbial hosts or the formulation of liposomes for drug delivery. We can also serve as your introduction to Dow Plant-Based Biopharmaceuticals, a related Dow business involved with the breeding, production and harvesting of therapeutic genes in plants that can be transformed into bulk drug materials. Broad capabilities specific to the biopharmaceutical industry include:
・High-expression vector development
・Formulation development and stability program execution
・cGMP manufacturing scale up
ANGUS Chemical Company http://www.dow.com/angus/
More than Nitroparaffins . . . We
Deliver Great Solutions!
You’ve known ANGUS Chemical Company as the primary manufacturer and marketer of nitroparaffin-based chemicals, supplying chemical intermediates such as nitromethane, AMP-95TM 2-amino-2-methyl-1-propanol, TRIS AMINOTM Tris (Hydroxymethyl) Aminomethane, IPHA I-15, ZOLDINETM oxazolidines and NiPar Solvents TM to name a few.
We are now more than just a nitroparaffin manufacturer and marketer ー we are in the business of delivering great solutions to our customers for applications in latex paints, mineral slurries, metalworking fluids, water treatment, biological buffers, solvents & thinners, wood adhesives, pharmaceutical & agricultural intermediates, SBR latex shortstops, fuel additives and personal care & household products.
Dow and TransCanada Pipelines Limited agree to a deal in which Dow will acquire CanStates Holdings, Inc., and its subsidiary, ANGUS Chemical Company. The acquisition is expected to help Dow reinforce its goals of expanding within the area of Performance Chemicals.